Search | Clinical Trials Finder

Conditions: Bacterial Infections
Interventions: Central Venous Catheter; Device
Lead sponsor: Angiotech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 21
States / cities: Birmingham, Alabama • Orange, California • San Diego, California + 17 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 18 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 33
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 21 more

Conditions: HIV Infection
Interventions: Vitamin D3 50,000 IU, Vitamin D3 placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more

Conditions: COVID-19, ARDS, Human, Stem Cells, Regeneration
Interventions: MRG-001, Placebo; Drug
Lead sponsor: MedRegen LLC; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: cyclosporine ophthalmic emulsion, placebo; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 5
States / cities: Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more

Conditions: HIV Infections
Interventions: Enfuvirtide, Highly active antiretroviral treatment (HAART); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Cleveland, Ohio • Austin, Texas • Dallas, Texas

Conditions: Covid19
Interventions: COVI-AMG, Placebo; Biological · Drug
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 4
States / cities: Garden Grove, California • Bradenton, Florida • Miami, Florida + 1 more

Conditions: SARS-CoV-2
Interventions: Secutrelvir, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 12 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Coral Gables, Florida • Miami, Florida • St. Petersburg, Florida + 2 more

Conditions: Shigellosis
Interventions: Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 8 Months to 50 Years
Enrollment: 597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 0
States / cities: Not listed

Conditions: HIV Infections, HIV
Interventions: IL-7; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prosthetic Joint Infection
Interventions: Phage Therapy, Two-Stage Exchange Arthroplasty; Biological · Procedure
Lead sponsor: Adaptive Phage Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions: Capsaicin Dermal Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 35
States / cities: Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more

Conditions: Clostridium Difficile Infection, Diarrhea
Interventions: CB-183,315, Placebo, Vancomycin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 22
States / cities: Washington D.C., District of Columbia • Saint Cloud, Florida • Decatur, Georgia + 17 more

Conditions: Pneumonia, Idiopathic Pneumonia Syndrome
Interventions: Etanercept, Placebo plus corticosteroid; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 12
States / cities: Gainesville, Florida • Indianapolis, Indiana • Baltimore, Maryland + 9 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Sepsis, Gastroenteritis, Dehydration
Interventions: SonoSite Maxx Series Ultrasound System; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: Up to 21 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19, Pneumonia
Interventions: LY3127804, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more

Conditions: Scabies
Interventions: spinosad topical suspension, 0.9%, Placebo; Drug · Other
Lead sponsor: ParaPRO LLC; Industry
Eligibility: 4 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Elk Grove, California • Kissimmee, Florida • Miami, Florida + 1 more

Conditions: Covid19
Interventions: Niclosamide, Placebo; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 7 more

Conditions: Infection Control, Surgical Site Infection
Interventions: Intervention Cluster; Other
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: COVID-19
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Methylprednisolone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 28 Days to 2 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: La Jolla, California • Chicago, Illinois • St Louis, Missouri + 2 more

Conditions: Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions: Placebo, LX211; Drug
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more

Conditions: HIV Infections
Interventions: MN rgp120/HIV-1, TBC-3B Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 4
States / cities: Baltimore, Maryland • St Louis, Missouri • Nashville, Tennessee + 1 more

Search by objective public record fields.

Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment

Bacteriophage Therapy in Patients With Prosthetic Joint Infections

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

Study of CB-183,315 in Participants With Clostridium Difficile Infection

Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration

A Study of LY3127804 in Participants With COVID-19

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

Early Recognition and Response to Increases in Surgical Site Infections Using Optimized Statistical Process Control Charts: The Early 2RIS Study

A Study of Baricitinib (LY3009104) in Participants With COVID-19

The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.